BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14737055)

  • 1. G-CSF in solid tumor chemotherapy: a tailored regimen reduces febrile neutropenia, treatment delays and direct costs.
    Tsavaris N; Kosmas C; Gouveris P; Vadiak M; Dimitrakopoulos A; Karadima D; Pagouni E; Panagiotakopoulos G; Tzima E; Ispoglou S; Sakelariou D; Koufos C
    Med Sci Monit; 2004 Feb; 10(2):PI24-8. PubMed ID: 14737055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
    Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
    Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
    Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual timing of blood counts in G-CSF prophylaxis after myelosuppressive chemotherapy reduces G-CSF injections, blood counts, and costs: a prospective randomized study in children and adolescents.
    Ammann RA; Leibundgut K; Hirt A; Ridolfi Lüthy A
    Support Care Cancer; 2002 Nov; 10(8):613-8. PubMed ID: 12436219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
    Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
    Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
    Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
    Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Granulocyte colony-stimulating factor in the treatment of febrile neutropenia].
    López-Hernández MA; Jiménez-Alvarado R; Borbolla-Escoboza R; de Diego Flores-Chapa J; Alvarado-Ibarra M; González-Avante M; Trueba-Chrysti ME; Anaya-Cuéllar I
    Gac Med Mex; 2000; 136(2):99-105. PubMed ID: 10815320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.
    Hendler D; Rizel S; Yerushalmi R; Neiman V; Bonilla L; Braunstein R; Sulkes A; Stemmer SM
    Am J Clin Oncol; 2011 Dec; 34(6):619-24. PubMed ID: 21217400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
    Morstyn G; Foote M; Perkins D; Vincent M
    Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.